<DOC>
	<DOCNO>NCT01961414</DOCNO>
	<brief_summary>The purpose research study determine `` Treat Extend '' regimen ( increase time visit disease stable get bad ) aflibercept 2.0mg injection inside eye treat patient Wet Age-related Macular Degeneration .</brief_summary>
	<brief_title>Treat Extend Therapy Study Using Intravitreal Aflibercept Patients Exited From Protocol VGFT-OD 0910</brief_title>
	<detailed_description>After exit VGFT-OD 0910 , patient enrol RANGE , longterm extension trial evaluate safety efficacy aflibercept IAI utilize `` treat extend '' regimen . Using pre-specified re-treatment criterion , treatment interval variable dose active treatment least every 12 week .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Previous enrollment 0910extension study evaluate intravitreal aflibercept injection ( NCT 00964795 ) without early study discontinuation prior sponsor early termination . Patients enrol within 90 day site activation ( attempt make ensure IAI give exit 0910extension prior enrollment ) . Willing able comply clinical visit study related procedure . Provide sign informed consent Prior treatment verteporfin , externalbeam radiation therapy , transpupillary thermotherapy study eye Previous subfoveal focal laser photocoagulation involve foveal center study eye History vitrectomy , submacular surgery , surgical intervention AMD study eye Any concurrent intraocular condition study eye ( e.g . diabetic retinopathy glaucoma ) , opinion investigator , could either require medical surgical intervention study period prevent treat visual loss might result condition , allow progress untreated , could likely contribute loss least 2 Snellen equivalent line best correct visual acuity study period Active intraocular inflammation ( grade trace ) study eye , history idiopathic autoimmuneassociated uveitis either eye Current vitreous hemorrhage study eye History rhegmatogenous retinal detachment macular hole ( Stage 3 4 ) study eye Active infectious conjunctivitis , keratitis , scleritis , endophthalmitis either eye Aphakia , ACIOL , unstable PCIOL Uncontrolled glaucoma study eye ( defined intraocular pressure â‰¥30 mmHg despite treatment antiglaucoma medication ) Pregnant breastfeed woman Sexually active men* woman childbearing potential** unwilling practice adequate contraception study ( adequate contraceptive measure include stable use oral contraceptive prescription pharmaceutical contraceptive 2 menstrual cycle prior screen ; intrauterine device [ IUD ] ; bilateral tubal ligation ; vasectomy ; condom plus contraceptive sponge , foam , jelly , diaphragm plus contraceptive sponge , foam , jelly ) Contraception require men document vasectomy . Postmenopausal woman must amenorrheic least 12 month order consider child bear potential . Pregnancy test contraception require woman document hysterectomy tubal ligation .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Exudative</keyword>
	<keyword>AMD</keyword>
	<keyword>Macular</keyword>
	<keyword>Degeneration</keyword>
	<keyword>Aflibercept</keyword>
	<keyword>Eylea</keyword>
	<keyword>Intravitreal</keyword>
</DOC>